Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07290803 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Study acronym: ARMADA-AD
StatusRecruiting
PhaseNot specified
SponsorSanofi
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 2 of 19 entries
    • Trial sites expanded: 79 → 82 locations
    • Eligibility criteria expanded, about 6 words
    • Secondary endpoints: details revised at 6 of 16 entries
  2. Trial sites expanded: 59 → 79 locationsv9
  3. Trial sites expanded: 56 → 59 locationsv8
  4. Trial sites expanded: 43 → 56 locationsv7
  5. Trial sites expanded: 37 → 43 locationsv6
Show 4 earlier versionsHide 4 earlier versions
  1. Study sites: 35 to 37v5
  2. Study sites: 16 to 35v4
  3. Study sites: 6 to 16
    • Eligibility criteria expanded, about 20 words
    v3
  4. Study sites: 9 to 6v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Sanofi
284 trials monitored
See 12 trials at risk
Atopic Dermatitis
500 trials monitored
See 16 trials at risk
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions. The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.
Trial Details
NCT Number NCT07290803
Lead Sponsor Sanofi
Conditions
(from sponsor)		 Atopic Dermatitis
Related terms Dermatitis, Atopic
Enrollment 1,000 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov